References

  1. Cordier JF, Chailleux E, Lauque D et al. Primary pulmonary lymphomas: a clinical study of 70 cases in non immunocompromised patients. Chest. 1993; 103(1): 201-8. PubMed | Google Scholar

  2. Ferraro P, Trastek VF, Adlakha H et al. Primary non-Hodgkin's lymphoma of the lung. Ann Thorac Surg. 2000; 69(4): 993-7. PubMed | Google Scholar

  3. Raderer M, Vorbeck F, Formanek M et al. Importance of extensive staging in patients with mucosa-associated lymphoid tissue (MALT)-type lymphoma. Br J Cancer. 2000; 83(4): 454-7. PubMed | Google Scholar

  4. Swerdlow SH. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues-4th edition, Lyon, France IARC. 2008. Google Scholar

  5. Ridene I, Radhouani I, Ayadi A et al. Imagerie des lymphomes pulmonaires primitifs. Rev Mal Respir. 2010; 27(9): 1069-76. Google Scholar

  6. Zucca E, Conconi A, Pedrinis E et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood. 2003; 101(7): 2489-95. PubMed | Google Scholar

  7. Wislez M, Cadranel J, Antoine M et al. Lymphoma of pulmonary mucosa-associated lymphoid tissue: CT scan findings and pathological correlations. Eur Respir J. 1999; 14(2): 423-9. PubMed | Google Scholar

  8. Perry C, Herishanu Y, Metzer U et al. Diagnostic accuracy of PET/CT in patients with extranodal marginal zone MALT lymphoma. Eur J Haematol. 2007; 79(3): 205-9. PubMed | Google Scholar

  9. Gaucher D, Bodaghi B, Charlotte F et al. Lymphome oculaire de type MALT simulant une sclérite ou une uvéite postérieure. J Fr Ophtalmol. 2005; 28(1): 31-8. Google Scholar

  10. Zucca E, Conconi A, Laszlo D et al. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study. J Clin Oncol. 2013; 31(5): 565-72. PubMed | Google Scholar